@article{3c9169167c094f9b801c525990cde492,
title = "Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice",
abstract = "The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. This review reports that the significance of a re-biopsy varies depending on the clinical situation.",
keywords = "Lung cancer, Re-biopsy, Treatment",
author = "Katsuyuki Hotta and Kiichiro Ninomiya and Eiki Ichihara and Katsuyuki Kiura",
note = "Funding Information: KH has received honoraria outside the current work from AstraZeneca, Ono Pharmaceutical, Astellas, Novartis, BMS, MSD, Eli Lilly Japan, Daiichi-Sankyo Pharmaceutical, Boehringer-Ingelheim, Nihon Kayaku, Taiho Pharmaceutical, and Chugai Pharmaceutical. KH has also received research funding outside the current work from AstraZeneca, Boehringer-Ingelheim, Ono Pharmaceutical, Astellas, Novartis, BMS, Eli Lilly Japan, MSD, and Chugai Pharmaceutical. KK has received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, and Sanofi-Aventis. Publisher Copyright: {\textcopyright} 2018, Japan Society of Clinical Oncology.",
year = "2019",
month = jan,
day = "22",
doi = "10.1007/s10147-018-1344-x",
language = "English",
volume = "24",
pages = "41--45",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "1",
}
